Targets › LAGE1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jul 2028.
Open in Phaseline: the race on LAGE1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| USWM CT | letetresgene autoleucel (lete-cel, GSK3377794) genetically engineered T cells targeting NY-ESO-1 (CTAG1B) and LAGE-1a | CTAG1B, LAGE1 | Phase 2 | Neoplasms | Jul 2028 |
Neoplasms (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.